Latest news

ElsaLys Biotech announces submission of Biologics License Application to FDA for LEUKOTAC® (inolimomab) for the treatment of graft-versus-host disease in adult patients

Thu, 07/23/2020 - 14:00

  • The Biologics License Application (BLA) will be rev

Read more

Mediolanum Farmaceutici acquires the French company ElsaLys Biotech to develop next generation immuno-oncology therapies

Thu, 05/07/2020 - 10:30

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its

Read more

LEUKOTAC ® (inolimomab) is available again in France, following the granting of cohort ATU for the treatment of graft-versus-host disease, corticosteroid-resistant or corticosteroid-dependent, with grade II-IV

Thu, 01/09/2020 - 13:00

  • The French National Agency for the Medicines and Health Products Safety (ANSM) granted a Temporary Authorisation for Use (ATU) so-call

Read more

ELSALYS BIOTECH has benefited from the support of the Auvergne Rhône Alpes Region

Wed, 05/08/2019 - 08:00

In 2015, the single interministerial fund (FUI) approved the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project, led by a consortium o

Read more

BioWorld - Elsalys looks to cross goal line in SR-aGVHD on positive long-term OS

Mon, 02/18/2019 - 09:46

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)

Read more

Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD

Wed, 01/23/2019 - 15:00
  • Follow-up of INO-107 Phase III study patients up to 8.5 years is the first long term analysis of a randomized study in acute steroid
Read more

Elsalys Biotech participates in JP Morgan Healthcare Conference

Mon - 10, 01/07 - 10/2019 - 08:00

Visit JP Morgan's Website

Read more

1st edition of the Days of the "antibody CLub" of the French Society of Immunology

Thu - 09, 11/08 - 09/2018 - 08:30

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Subscribe now
Copyright 2018 ElsaLys Biotech SA

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.